Gilead Sciences, Inc. (NASDAQ:GILD) will announce its earnings results after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $2.11 per share for the quarter.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.08 earnings per share. On average, analysts expect Gilead Sciences to post $8.74 EPS for the current fiscal year and $7.37 EPS for the next fiscal year.

Shares of Gilead Sciences, Inc. (GILD) opened at 81.21 on Monday. The company has a market cap of $106.05 billion, a P/E ratio of 8.82 and a beta of 1.14. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The stock’s 50 day moving average price is $82.63 and its 200-day moving average price is $72.65.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

GILD has been the topic of several recent research reports. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price objective on the stock in a report on Monday, June 26th. Jefferies Group LLC reissued a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 4th. J P Morgan Chase & Co reissued an “overweight” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 4th. Cowen and Company reissued an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a report on Wednesday, July 5th. Finally, Morgan Stanley reissued an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $85.64.

WARNING: “Gilead Sciences, Inc. (GILD) to Release Quarterly Earnings on Monday” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/gilead-sciences-inc-gild-to-release-quarterly-earnings-on-monday.html.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP James R. Meyers sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $83.19, for a total value of $4,991,400.00. Following the completion of the transaction, the executive vice president now owns 62,715 shares in the company, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. Insiders sold a total of 446,819 shares of company stock worth $36,338,919 in the last 90 days. Company insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Keel Point LLC boosted its stake in shares of Gilead Sciences by 0.4% in the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 12 shares during the last quarter. National Asset Management Inc. boosted its stake in shares of Gilead Sciences by 0.7% in the 2nd quarter. National Asset Management Inc. now owns 26,270 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 174 shares during the last quarter. Linscomb & Williams Inc. boosted its stake in shares of Gilead Sciences by 10.1% in the 2nd quarter. Linscomb & Williams Inc. now owns 5,806 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 531 shares during the last quarter. Stellar Capital Management LLC boosted its stake in shares of Gilead Sciences by 10.2% in the 2nd quarter. Stellar Capital Management LLC now owns 14,761 shares of the biopharmaceutical company’s stock worth $1,045,000 after buying an additional 1,366 shares during the last quarter. Finally, Rowland & Co. Investment Counsel ADV purchased a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $153,000. Hedge funds and other institutional investors own 73.97% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.